Profund Advisors LLC boosted its holdings in shares of Insmed, Inc. (NASDAQ:INSM – Free Report) by 144.8% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 27,844 shares of the biopharmaceutical company’s stock after purchasing an additional 16,471 shares during the quarter. Profund Advisors LLC’s holdings in Insmed were worth $4,846,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently bought and sold shares of the company. CIBC Private Wealth Group LLC raised its position in Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 53 shares during the last quarter. CoreCap Advisors LLC purchased a new position in Insmed during the 4th quarter worth approximately $27,000. SBI Securities Co. Ltd. raised its position in Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 166 shares during the last quarter. GraniteShares Advisors LLC purchased a new position in Insmed during the 4th quarter worth approximately $30,000. Finally, Whittier Trust Co. of Nevada Inc. raised its position in Insmed by 169.7% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 151 shares during the last quarter.
Insider Activity
In other news, insider Michael Alexander Smith sold 19,638 shares of Insmed stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the completion of the transaction, the insider directly owned 51,871 shares of the company’s stock, valued at $7,831,483.58. The trade was a 27.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO William Lewis sold 10,699 shares of Insmed stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $143.97, for a total transaction of $1,540,335.03. Following the transaction, the chief executive officer directly owned 301,185 shares of the company’s stock, valued at approximately $43,361,604.45. This trade represents a 3.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 161,193 shares of company stock valued at $25,462,012 in the last three months. 2.10% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Report on INSM
Insmed Price Performance
NASDAQ:INSM opened at $107.15 on Tuesday. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10. The firm has a market cap of $23.22 billion, a price-to-earnings ratio of -18.63 and a beta of 0.89. The company has a 50 day moving average price of $140.60 and a 200-day moving average price of $162.84. Insmed, Inc. has a 1-year low of $64.85 and a 1-year high of $212.75.
Insmed (NASDAQ:INSM – Get Free Report) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.14. The firm had revenue of $305.96 million during the quarter, compared to analyst estimates of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The business’s quarterly revenue was up 229.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.42) EPS. Equities research analysts forecast that Insmed, Inc. will post -2.52 EPS for the current year.
Insmed Company Profile
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.
The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.
Further Reading
- Five stocks we like better than Insmed
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM – Free Report).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.
